We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dual blocking of PI3K and mTOR signaling by DHW‐221, a novel benzimidazole derivative, exerts antitumor activity in human non‐small cell lung cancer.
- Authors
Qin, Xiaochun; Liu, Mingyue; Wu, Yuting; Wang, Shu; Lian, Siheng; Jia, Hui; Wu, Qiong; Ding, Huaiwei; Zhao, Qingchun
- Abstract
GLO:F2H7/01sep21:ctm2514-fig-0001.jpg PHOTO (COLOR): 1 DHW-221 is a PI3K/mTOR dual-target inhibitor and inhibits the PI3K/AKT/mTOR signaling pathway. Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer (E, G) Western blot was also used to evaluate the effects of DHW-221 on PI3K/AKT/mTOR pathway-related proteins in non-small cell lung cancer (NSCLC) cells and tissues (n = 6). We previously designed and synthesized a novel benzimidazole compound, DHW-221.1 Here, we evaluated its anti-NSCLC activity as a PI3K/mTOR dual-target inhibitor and comprehensively described for the first time the mechanism underlying the PI3K/AKT/mTOR signaling pathway-mediated antitumor effects of DHW-221.
- Subjects
NON-small-cell lung carcinoma; PHOSPHATIDYLINOSITOL 3-kinases; BENZIMIDAZOLE derivatives; CELL physiology; PATHOLOGICAL physiology; SHAPE memory polymers
- Publication
Clinical & Translational Medicine, 2021, Vol 11, Issue 9, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.514